Complications of Tissue Plasminogen Activator Therapy After Vitrectomy for Diabetes
- 1 October 1990
- journal article
- research article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 110 (4) , 354-360
- https://doi.org/10.1016/s0002-9394(14)77014-x
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Tissue Plasminogen ActivatorNew England Journal of Medicine, 1988
- Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarctionThe American Journal of Medicine, 1988
- Treatment of Postvitrectomy Fibrin Formation With Intraocular Tissue Plasminogen ActivatorArchives of Ophthalmology (1950), 1988
- Intravitreal Clearance of Tissue Plasminogen Activator in the RabbitArchives of Ophthalmology (1950), 1988
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988
- Thrombolysis in myocardial infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activatorJournal of the American College of Cardiology, 1987
- Use of Tissue Plasminogen Activator in Experimental HyphemaArchives of Ophthalmology (1950), 1987
- Fibrin: Mediator ofin vivoandin vitroinjury and inflammationCurrent Eye Research, 1985
- Effect of Fibrin on Morphologic Characteristics of Retinal Pigment Epithelial CellsArchives of Ophthalmology (1950), 1984
- TOXIC OCULAR EFFECTS OF TWO FIBRINOLYTIC DRUGSActa Ophthalmologica, 1983